Abstract
Breast cancer incidence is increased in elderly women. Since these patients were mostly excluded in prospective randomized studies, no firm recommendations currently exist for the management of breast cancer in elderly. It is highly probable that older women have one or more significant co-morbid diseases and moreover, their functional capacity is independently reduced. Also, previous studies provided that biological features of breast cancer are favourable in older women. Observational reports showed that older women with breast cancer are currently undertreated when compared to their younger counterparts. In previous studies targeting exclusively elderly breast cancer patients, primary hormonotherapy without further excision of operable tumors, breast conserving surgery without adjuvant radiotherapy to whole breast and, as well as ommision of axillary surgery in clinically node negative patients were questioned, seperately. In this comprehensive review, all available evidences regarding surgical treatment of breast cancer in elderly are provided in order to assess the rationality of these treatment diversions. As a conclusion, before implementing these less aggresive treatment modalities in physiologically fit elderly, results of studies with high power and longer follow-up should be awaited. Therefore, omission of standart treatment modalities should be regarded only for frail elderly with decreased life expectancy.
Keywords:
breast cancer, surgery, primary hormonotherapy, elderly
References
1
Louwman WJ, Vulto JCM, Verhoeven RHA, Nieuwenhuijzen GAP, Coebergh JWW, Voogd AC. Clinical epidemiology of breast cancer in the elderly. Eur J Cancer 2007;43:2242-2252.
2
Molino A, Giovannini M, Auriemma A, Fiorio E, Mercanti A, Mandara M, Caldara A, Micciolo R, Pavarana M, Cetto GL. Pathological, biological and clinical characteristics, and surgical management of elderly women with breast cancer. Crit Rev Oncol Hematol 2006;59:226-233.
3
Diab SG, Elledge RM, Clarke GM. Tumour characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2000;92:550-556.
4
Caywood J, Gray RJ, Hentz J, Pockaj BA. Older age independently predicts a lower risk of sentinel node metastasis in breast cancer. Ann Surg Oncol 2005;12:1061- 1065.
5
Schaefer G, Rosen PP, Lesser ML, Kine DW, Beatie EJ. Breast carcinoma in elderly women: pathology, prognosis and survival. Pathol Ann 1984;19:195-218.
6
Wyld L, Reed M. The role of surgery in the management of older women with breast cancer. Eur J Cancer 2007;43:2253- 2263.
7
MacDonald BK, Cockerell OC, Sanders WAS, Shorvon SD. The incidence and lifetime prevalence of neurological disorders in a prospective community based study in the UK. Brain 2000;123:665-676.
8
Lindberg A, Eriksson B, Larsson L-G, Ronmark E, Sandstrom T, Lundback B. Seven year cumulative incidence of COPD in an age stratified general population sample. Chest 2006;129:879-885.
9
Satarino WA, Ragland DR. The effect of co-morbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994;120:104-110.
10
Fennessey M, Bates T, McRae K, Riley D, Houghton J, Baum M. Randomised trial of surgery plus tamoxifen versus tamoxifen-alone in women over age 70 with operable breast cancer. Br J Surg 2004;91:699-704.
11
Mustacchi G, Ceccherini R, Milani S, Pluchinotta A, De Matteis A, Maiorino L, Farris A, Scanni A, Sasso F; Italian Cooperative Group GRETA. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol 2003;14:414-420.
12
Fentiman IS, Christiaens MR, Paridaens R, Van Geel A, Rutgers E, Berner J, de Keizer G, Wildiers J, Nagadowska M, Legrand C, Therasse P; EORTC. Treatment of operable breast cancer in the elderly: a randomized clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy. Eur J Cancer 2003;39:309-316.
13
Kenny FS, Robertson JFR, Ellis IO, Elston CW, Blamey RW. Long term follow-up of elderly patients randomized to primary tamoksifen or wedge mastectomy as initial therapy for operable breast cancer. Breast 1998;7:335-339.
14
Gazet JC, Ford HT, Coombs RC, Bland JM, Sutcliffe R, Quilliam J, Lowndes S. Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer. Eur J Surg Oncol 1994;20:207-214.
15
Hind D, Wyld L, Beverley CB, Reed MW. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No. CD004272. DOI:10.1002/14651858.CD004272.pub2.
16
http://www.thelancet.com/protocolreviews/ 07PRT-4338 adresinden 22 Mayıs 2009 tarihinde erişilmiştir.
17
Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Eng J Med 2002;347:1233-1241.
18
Blichert-Toft M, Nielsen M, During M, Moller S, Rank F, Overgaard M, Mouridsen HT. Long-term results of breast conserving surgery vs mastectomy for early stage invasive breast cancer: 20-year follow- up of the Danish randomized DBCG- 82TM protocol. Acta Oncol 2008;47:672- 681.
19
DeHaes JCJM, Curran D, Aaronson NK, Fentiman IS. Quality of life in breast cancer patients aged over 70 years, participating in the EORTC 10850 randomised clinical trial. Eur J Cancer 2003;39;945- 951.
20
Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinnon E, Mc- Gale P, McHugh T, Peto R, Taylor C, Wang Y; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087-2106.
21
Martelli G, Miceli G, Costa A, Coradini D, Zurrida S, Piromalli D, Vetrella G, Greco M. Elderly breast cancer patients treated by conservative surgery alone plus adjuvant tamoxifen: fifteen-year results of a prospective study. Cancer 2008;112:481- 488.
22
Fyles AW, McCready DR, Manchul LA, Trudeau ME, Merante P, Pintilie M, Weir LM, Olivotto IA. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Eng J Med 2004;351:963-970.
23
Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, Wheeler J, Champion LA, Smith TJ, Smith BL, Shapiro C, Muss HB, Winer E, Hudis C, Wood W, Sugarbaker D, Henderson IC, Norton L. Lumpectomy plus tamoxifen with or without irradiation in women over 70 years of age or older with early breast cancer. N Eng J Med 2004;351:971- 977.
24
http://homepages.ed.uc.uk/prime/ prime2.html adresinden 22 Mayıs 2009 tarihinde erişilmiştir.
25
Prescott RJ, Kunkler IH, Williams LJ, King CC, Jack W, van der Pol M, Goh TT, Lindley R, Cairns J. A randomized controlled trial of postoperative radiotherapy following breast-conserving surgery in a minimum-risk older population. The PRIME trial. Health Technol Assess 2007;11:1-149, iii-iv
26
Martelli G, Boracchi P, De Palo M, Pilotti S, Oriana S, Zucali R, Daidona MG, De Palo G. A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: results after 5 years of follow-up. Ann Surg 2005;242:1-6.
27
International Breast Cancer Study Group, Rudenstam CM, Zahrieh D, Forbes JF, Crivellari D, Holmberg SB, Rey P, Dent D, Campbell I, Bernhard J, Price KN, Castiglione-Gertsch M, Goldhirsch A, Gelber RD, Coates AS. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group trial 10-93. J Clin Oncol 2006;24:337-344.
28
Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, Cochran AJ, Cody HS 3rd, Edge SB, Galper S, Hayman JA, Kim TY, Perkins CL, Podoloff DA, Sivasubramanian VH, Turner RR, Wahl R, Weaver DL, Wolff AC, Winer EP; American Society of Clinical Oncology. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005;23:7703-7720.
29
Chagpar AB, McMasters KM, Edwards MJ; North American Fareston Tamoxifen Adjuvant Trial. Can sentinel node biopsy be avoided in some elderly breast cancer patients? Ann Surg 2009;249:455-460.
30
McMahon LE, Gray RJ, Pockaj BA. Is breast cancer sentinel lymph node mapping valuable for patients in their seventies and beyond? Am J Surg 2005;190:366- 370.
